The approval was supported by data from the phase 3 OPTIMA trial, which enrolled 63 adults with FOP confirmed by an ACVR1 FOP ...

Intismeran autogene is a personalized mRNA therapy that targets a tumor's unique mutational signature to trigger an anticancer immune response.

Coverage slipped for every required shot, with declines in more than half of states for a second straight year.

Most cases accounted for by medication-related exposures, with acetaminophen alone most frequently implicated.

The non-pharmacologic nasal mist uses hydroxypropyl methylcellulose to form a protective physical barrier in the nasal passages, trapping and blocking airborne allergens.

Nearly 1 in 4 patients treated with lecanemab for mild cognitive impairment or mild Alzheimer disease (AD) with confirmed amyloid pathology develop amyloid-rela ...

The phase 3 ALKIVIA study met its primary endpoint, demonstrating significant and sustained improvements in disease activity and muscle strength for patients with active autoimmune myositis.

Lerochol autoinjector is expected to launch by January 2027. The Food and Drug Administration (FDA) has approved a new once-monthly autoinjector presentation of Lerochol ® (lerodalcibep-liga), a third ...

Many people with atypical Alzheimer disease (AD) do not meet eligibility criteria for anti-amyloid therapies (AAT), according to a study published online August 5 in Neurology. Dror Shir, MD, from the ...

States are moving faster and further than federal regulators to get kratom off store shelves, with some banning the herb outright while a pending federal rule targets only one of its chemicals.

Adding iberdomide to daratumumab and dexamethasone significantly increased the MRD-negative complete response rate to 41% vs 21% with DVd in patients with RRMM. The Food and Drug Administration (FDA) ...

The device enables eligible adult wheelchair users living with spinal cord injury to walk and perform some activities of daily living.